Key result
Pacemaker therapy in patients ≥85 yields ~45% 5-year survival, with similar mortality across indications.
Why the study?
The number of very elderly patients receiving pacemakers is increasing, but little is known about survival and prognostic variables associated with death in this specific subgroup.
What are the survival outcomes and prognostic parameters in patients aged ≥ 85 years receiving pacemaker therapy?
Cohort (n=572)
No
What are the survival outcomes and prognostic parameters in patients aged ≥ 85 years receiving pacemaker therapy?
Pacemaker therapy is a clinically effective option providing good life expectancy in patients aged ≥ 85 years, with non-cardiac comorbidities being the primary drivers of mortality.
Answers are grounded in this paper and cite their sources.
May support pacemaker consideration in selected patients ≥85 years; leaves open whether indication type influences mortality beyond comorbidities.
Background Permanent pacing is the therapy of choice for treating severe and/or symptomatic bradyarrhythmias. The number of very elderly patients receiving pacemakers is increasing and little is known about survival in this specific subgroup. This study is aimed at assessing the actual survival of patients requiring pacing therapy at age > 85 years and investigating variables associated with death. Methods Between 2010 and 2017, 572 patients aged ≥ 85 years underwent pacemaker implantation for conventional bradycardia indications in Department of Cardiology, S. Chiara Hospital, Italy. Results Thirty percent of patients were ≥ 90-year-old and comorbidities were frequent. Fifty-seven percent of patients required pacing for prognostic reasons (acquired atrioventricular block), and the remaining for relief of bradycardia symptoms. A dual-chamber pacemaker was implanted in 34% of patients. The 5-year survival was 45% (standard error: 3%), and the 8-year survival was 26% (standard error: 4%). The risk of death was similar in patients who received pacemaker for symptom relief and for prognostic reasons in the overall population (HR = 1.19, 95% CI: 0.93–1.52, P = 0.156), as well as in the ≥ 90-year-old group (HR = 1.39, 95% CI: 0.92–2.11, P = 0.102). At multivariate analysis, following variables were associated with death: higher age, lower ejection fraction, dementia/dysautonomia and diagnosis of cancer. The pacing indication and the implantation of a single chamber pacemaker were not associated with worse prognosis. Conclusions This study showed a good life expectancy in patients aged ≥ 85 years who received a pacemaker. Strong risk factors for all-cause death were non-cardiac. Pacemaker therapy seems a clinically effective therapeutic option to improve survival and to control bradyarrhythmia-related symptoms in very elderly patients.
No takes yet. Share an insight, caveat, or question.
Marini et al. (2019) conducted a cohort in Severe and/or symptomatic bradyarrhythmias requiring permanent pacing (n=572). Pacemaker implantation for bradycardia symptom relief vs. Pacemaker implantation for prognostic reasons (acquired atrioventricular block) was evaluated on All-cause mortality (HR 1.19, 95% CI 0.93–1.52, p=0.156). Pacemaker therapy in patients aged ≥85 years yielded a 45% 5-year survival, with similar mortality risk between symptom relief and prognostic indications.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: